- Verana Health recently announced that they raised $150 million in Series E funding. These are the details.
Verana Health — a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network — recently announced a $150 million Series E funding round led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings.
Verana Health will use the funding to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships.
Existing Verana Health investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the funding round, as well as notable new investors, including the Merck Global Health Innovation Fund, THVC, and Breyer Capital.
With this additional capital, Verana Health is poised to accelerate its position as a market leader in powering quality real-world data to drive quality insights across the drug lifecycle. The company will build upon its strong technology and data ecosystem — the VeraQ — platform and its curated Qdata in ophthalmology, neurology, and urology—to advance clinical trials enablement, software-as-a-service, and real-world evidence. Plus the company will also expand upon its established artificial intelligence (AI) capabilities with a particular focus on its pioneering use of natural language processing (NLP) to extract insights from unstructured text data in electronic health record (EHR) notes.
In October 2021, Verana Health launched its VeraQ population health data engine, which is clinician-directed and enhanced by AI to securely power a data integrity feedback loop of nearly a half-billion, de-identified healthcare encounters. And the outcome is curated Qdata—disease-specific, fit-for-purpose data modules designed to help life sciences companies confidently drive business insights and rigorously inform research outcomes.
KEY QUOTES:
“We’d like to thank both our existing and new investors for partnering with us, demonstrating confidence in the foundation we’ve built through our exclusive real-world data network and our advanced population health data engine, VeraQ. We’re especially pleased to have a strong mix of investors—including growth firms, life sciences innovation funds, and academia—who recognize the momentum we’ve built in powering real-world evidence by cultivating exclusive partnerships with three specialty medical societies and collaborating with four of the top-five pharmaceutical companies.”
— Sujay Jadhav, CEO of Verana Health
“The healthcare industry needs new ways of creating high-quality data sets from disorganized information dispersed throughout a myriad of electronic health record systems that often lack interoperability and standardization. Verana Health is solving this critical need by delivering and analyzing proprietary, curated data sets (Qdata), from both structured and unstructured data that maintain truth to original clinical context. The company is well-positioned to help healthcare providers advance quality care standards, and life sciences companies accelerate clinical research and bring products to market that benefit both patients and physicians.”
— David W. Parke II, MD, Verana Health’s Executive Chairman and CEO of its first medical society partner, the American Academy of Ophthalmology
“Verana Health has shown incredible growth in its collaboration with leading pharmaceutical companies and medical societies. The Company has assembled a seasoned management team with deep experience in healthcare, science, and business that will continue to expand real-world evidence into multiple therapeutic areas with its unique and powerful health data platform, VeraQ. We are pleased to join Verana Health’s investors and look forward to working with the team to generate insights that ultimately help to improve quality of life for patients.”
— Jeffrey Low, MD, Principal at Novo Growth
